CAVERJECT Sterile Powder contains alprostadil as the naturally occurring form of prostaglandin E1 (PGE1) and is designated chemically as (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid.
CAVERJECT is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
Intracavernosal CAVERJECT may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
Published Studies Related to Caverject (Alprostadil)
Alprostadil infusion in patients with dry age related macular degeneration: a
randomized controlled clinical trial. 
alprostadil infusion in patients with dAMD... CONCLUSION: A numerical treatment effect in favor of alprostadil was visible,
[Clinical effects of alprostadil injection on acute kidney injury after cardiac surgical procedures]. [2010.08.24]
OBJECTIVE: To explore the clinical effects of alprostadil injection on acute kidney injury (AKI) after cardiac surgical procedures by a prospective randomized controlled trial... CONCLUSION: On the basis of routine therapy, alprostadil injection may promote the recovery of renal function in AKI-patients after cardiac surgical procedures.
Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. [2010.06]
PURPOSE: To our knowledge we report the first large, randomized, prospective penile rehabilitation clinical trial to compare the effectiveness of nightly intraurethral alprostadil vs sildenafil citrate after nerve sparing prostatectomy... CONCLUSIONS: This is the first study to directly compare the ability of alprostadil and a phosphodiesterase-5 inhibitor to enhance penile recovery subsequent to bilateral nerve sparing radical prostatectomy. The use of nightly subtherapeutic intraurethral alprostadil is well tolerated after radical prostatectomy. The benefit to return of erectile function of nightly sildenafil citrate and subtherapeutic intraurethral alprostadil appears to be comparable within the first year of surgery. Copyright 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. [2009.02]
INTRODUCTION: Alprostadil is approved for treatment of male erectile dysfunction (ED) by injection or urethral insertion. Topical delivery of alprostadil offers an improved alternative. AIM: To evaluate the long-term safety and efficacy of topical alprostadil cream... CONCLUSIONS: Topical alprostadil cream was considered effective and safe by most patients and their partners, with most AEs limited to the application site. Dose adjustment to 300 mcg alprostadil facilitated the greatest improvement in erectile function in the majority of patients. A separate report will integrate patient data from the open-label extension and prior double-blind studies.
[Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases] [2008.11.11]
OBJECTIVE: To investigate the therapeutic effects of alprostadil (Lipo-PGE1) and Ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass (CPB) in pediatric patients with congenital heart diseases... CONCLUSION: Decreasing the inflammatory response after CPB, alprostadil and ulinastatin used during CPB effectively reduce the pulmonary injury via inhibition of the neutrophil activation and cytokines release.
Clinical Trials Related to Caverject (Alprostadil)
The Use of Prostaglandin E1 in Head and Neck Microsurgery [Recruiting]
Prostaglandin E1 (PGE1 )has been shown to have vasodilatation and anti-thrombosis effects,
so it is used by some surgeons after microsurgery to keep the patency of the anastomosed
small vessels. However, PGE 1 may also causes some complications, like pleural effusion or
deep vein thrombosis. Therefore, it remains uncertain whether a routine use of PGE 1 after
head and neck microsurgery is justified. We aim to test the hypothesis that PGE 1 increases
postoperative vessel patency rate in patients undergoing head and neck microsurgery, with a
comparable complication rate as the control group.
Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention [Not yet recruiting]
we hypothesized that periprocedural treatment with intravenous lipo-PGE1 may reduce
myocardial injury and improve clinical outcomes in patients undergoing PCI.
Prostaglandin E1 in Outpatients With Intermittent Claudication [Completed]
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with
Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the
pain-free walking distance in patients with Intermittent Claudication.
Alprostadil in Maculopathy Study (AIMS) [Terminated]
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV [Completed]
The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on
the rate of complete healing of ischemic necroses and ulcerations as well as on the
frequency and height of major amputations in patients suffering from PAOD stage IV.
Reports of Suspected Caverject (Alprostadil) Side Effects
Drug Ineffective (26),
Penis Disorder (7),
Erectile Dysfunction (6),
Penile Pain (5),
Expired Drug Administered (5),
Drug Effect Decreased (5),
Erection Increased (5),
Peyronie's Disease (4),
Poor Quality Drug Administered (4),
Prostatic Disorder (3), more >>